#medicaldevice #ipo
🇺🇸 #EARGO
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $107M
✅ Valuation: $570M
✅ Revenue 1H2020: $29M
✅ EBIT: $-17M
✅ Net Income: $-18M
✅ Net Debt: $0M
✅ Total Addressable Market (TAM): $30 000M
✅ Upside: 36%
🧑🏻🦱 Founder: Raphael Michel
@freenewspaper
🇺🇸 #EARGO
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $107M
✅ Valuation: $570M
✅ Revenue 1H2020: $29M
✅ EBIT: $-17M
✅ Net Income: $-18M
✅ Net Debt: $0M
✅ Total Addressable Market (TAM): $30 000M
✅ Upside: 36%
🧑🏻🦱 Founder: Raphael Michel
@freenewspaper
#AI #medical #roundC
🇮🇱 🇺🇸 #MEDAWARE
✅ Stage: Round C
✅ Type: Equity
✅ Invest: $1,4M
✅ Valuation: $20M
✅ Revenue 2020: N/A
✅ Co-investors: GE Ventures, Strategic Chinese Investor
👨🏼🦳 Founder: Gidi Stein
@freenewspaper
🇮🇱 🇺🇸 #MEDAWARE
✅ Stage: Round C
✅ Type: Equity
✅ Invest: $1,4M
✅ Valuation: $20M
✅ Revenue 2020: N/A
✅ Co-investors: GE Ventures, Strategic Chinese Investor
👨🏼🦳 Founder: Gidi Stein
@freenewspaper
#cloud #ipo
🇺🇸 #DATTO HOLDING
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $561M
✅ Valuation: $4 300M
✅ Revenue (1H2020): $249M
✅ EBIT (1H2020): $30M
✅ Net Income (1H2020): $10M
✅ Net Debt (1H2020): $521M
✅ Total Addressable Market (TAM): $309 000M
✅ Market growth (CAGR): 10%
✅ Upside: 30%
@freenewspaper
🇺🇸 #DATTO HOLDING
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $561M
✅ Valuation: $4 300M
✅ Revenue (1H2020): $249M
✅ EBIT (1H2020): $30M
✅ Net Income (1H2020): $10M
✅ Net Debt (1H2020): $521M
✅ Total Addressable Market (TAM): $309 000M
✅ Market growth (CAGR): 10%
✅ Upside: 30%
@freenewspaper
#delivery #preseed
🇺🇸🇷🇺🇵🇱 #VIA.DELIVERY
✅ Stage: Pre-Seed
✅ Type: Equity
✅ Invest: $100K
✅ Valuation: on request
✅ MRR: $25K
🧑🏼🦰 CEO: Dmitrii Nikitin
@freenewspaper
🇺🇸🇷🇺🇵🇱 #VIA.DELIVERY
✅ Stage: Pre-Seed
✅ Type: Equity
✅ Invest: $100K
✅ Valuation: on request
✅ MRR: $25K
🧑🏼🦰 CEO: Dmitrii Nikitin
@freenewspaper
#robotic #preseed
🇪🇺🇷🇺 #INVENTORY VIEWE
✅ Stage: Pre-Seed
✅ Type: Equity
✅ Invest: EUR 0,7M
✅ Return: 60X in 5 years
✅ Valuation: EUR 2,8M
✅ Revenue (2020): EUR 0,5M
✅ Total Addressable Market (TAM): $19 000M
✅ Market growth (CAGR): 12%
👩🏼🦳 CEO: Anastasia Uryasheva
@freenewspaper
🇪🇺🇷🇺 #INVENTORY VIEWE
✅ Stage: Pre-Seed
✅ Type: Equity
✅ Invest: EUR 0,7M
✅ Return: 60X in 5 years
✅ Valuation: EUR 2,8M
✅ Revenue (2020): EUR 0,5M
✅ Total Addressable Market (TAM): $19 000M
✅ Market growth (CAGR): 12%
👩🏼🦳 CEO: Anastasia Uryasheva
@freenewspaper
#pharma #ipo
🇺🇸 #ATEA PHARMACEUTICALS
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $253M
✅ Valuation: $2 000M
✅ Revenue (1H2020): $0M
✅ EBIT (1H2020): $-14M
✅ Net Income (1H2020): $-14M
✅ Net Debt (1H2020): $0M
✅ Total Addressable Market (TAM): $40 000M
✅ Oversubscribed: Medium
(source: IPO Boutique)
✅ Analyst rating: Neutral
(source: IPO Boutique)
✅ Upside: 36%
@freenewspaper
🇺🇸 #ATEA PHARMACEUTICALS
✅ Stage: IPO
✅ Type: Equity
✅ Invest: $253M
✅ Valuation: $2 000M
✅ Revenue (1H2020): $0M
✅ EBIT (1H2020): $-14M
✅ Net Income (1H2020): $-14M
✅ Net Debt (1H2020): $0M
✅ Total Addressable Market (TAM): $40 000M
✅ Oversubscribed: Medium
(source: IPO Boutique)
✅ Analyst rating: Neutral
(source: IPO Boutique)
✅ Upside: 36%
@freenewspaper